FDA limits use of two COVID-19 antibody treatments due to omicron

The FDA removed two monoclonal antibody therapies from the list of COVID-19 treatments due to their ineffectiveness against the omicron variant, the agency said Jan. 24.

Advertisement

The use of bamlanivimab and etesevimab, which are administered together, and REGEN-COV are no longer authorized for use. The agency said if patients in certain geographic regions are likely to be infected or exposed to a variant that is susceptible to these treatments in the future, these treatments may be authorized in these regions.  

The Department of Health and Human Services notified state health officials Jan. 24 that distribution of the antibody medications has been halted as a result, The Washington Post reported. 

Florida Gov. Mike DeSantis closed all monoclonal antibody treatment sites in the state as a result of the decision. More than 2,000 appointments were canceled in the state for Jan. 25 alone, according to a statement from Mr. DeSantis’ office.

Several treatments remain effective against omicron — including sotrovimab, a monoclonal antibody made by GlaxoSmithKline and Vir Biotechnology — and the agency encouraged healthcare providers to consult the NIH panel’s COVID-19 treatment guidelines.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.